
How to read this finding
Discovery speed is specific to the reported campaign and does not establish a general reduction in drug-development time. Trial entry and animal activity are distinct stages; neither implies regulatory approval.
DSP-1181 entered a Phase 1 clinical trial in Japan. The report presented this as a milestone for AI-assisted discovery, not as an approved or proven treatment.

Discovery speed is specific to the reported campaign and does not establish a general reduction in drug-development time. Trial entry and animal activity are distinct stages; neither implies regulatory approval.
Evidence you can use
Historical snapshot: October 2020. Dates and populations are specified per row.
| Measure | Reported value | Definition and source |
|---|---|---|
| DSP-1181 development collaboration | 12 months | Reported collaboration leading to the candidate discussed in the report.2020 report, PDF page 83 |
| Candidates experimentally tested | 350 | Number reported for the DSP-1181 discovery campaign.2020 report, PDF page 83 |
| Halicin evidence stage | Activity in mice | Preclinical result, not human clinical efficacy.2020 report, PDF page 41 |
Discovery speed is specific to the reported campaign and does not establish a general reduction in drug-development time. Trial entry and animal activity are distinct stages; neither implies regulatory approval.
Historical snapshot published October 1, 2020. This web edition was prepared on 2026-10-11 from the online deck and original launch posts. Findings and forecasts retain their original time frame.
Benaich, Nathan, and Ian Hogarth. “What was the AI drug-discovery milestone in 2020?” State of AI Report 2020. Historical report snapshot; web edition prepared 2026-10-11.